Angle Plc Up 29% After News Release

PUBLISHED: 11 Nov 2011 @ 14:58 | Comments (0) |

In an RNS update on Friday, Angle Plc (LSE:AGL) announced that Parsortix Inc, its 90% owned subsidiary specializing in medical diagnostics, has confirmed that its cell separation device can capture prostate cancer cells.

The technology has previously been proven to capture breast cancer cells and this discovery is another step in demonstrating that Parsortix separation technology works well with all solid tumour cancers without modification. Other existing antibody affinity based technologies require this modification to treat different types of cancer.

This technology can help with early detection of cancer, monitoring patients during treatment, and post-treatment monitoring of patients whose cancer is in remission.

CEO Comments

CEO Andrew Newland Commented on the results:

“The successful capture and identification of prostate cancer cells added to blood further substantiates the potential for the Parsortix separation technology to become a market-leading product, which is simple, effective and affordable.”

Angle shares were up 29% in the late afternoon at 93.5 p on Friday.

Company Spotlight

Founded in 1994, Angle Plc is an AIM traded company focusing on the commercialisation of technology and the development of technology-based industry. They own a portfolio of company holdings with growth potential in the medical and technology sectors.

References
↑ RNS
↑ About Angle

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Plc. ADVFN Plc does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.